Updated Jul 16, 2026 · Last SEC filing 2026-06-18
Zentalis Pharmaceuticals, Inc. (ZNTL) has filed 6 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-18. 6 Form 8-K material event filings were reported by ZNTL in the last 90 days. InsiderAlpha tracks every ZNTL SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001725160 |
| Form 4 filings (90d) | 6 |
|---|---|
| Form 8-K filings (90d) | 6 |
| Latest Form 4 filing | 2026-06-18 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Myers Scott Dunseth | Director | A — Grant or award | 57.1K | $0.00 | — | SEC | |
| Kariuki Enoch | Director | A — Grant or award | 57.1K | $0.00 | — | SEC | |
| Walker Luke Nathaniel | Director | A — Grant or award | 57.1K | $0.00 | — | SEC | |
| Skvarka Jan | Director | A — Grant or award | 57.1K | $0.00 | — | SEC | |
| Johnson David Michael | Director | A — Grant or award | 57.1K | $0.00 | — | SEC | |
| Campbell Shannon | Director | A — Grant or award | 114.2K | $0.00 | — | SEC | |
| Vultaggio Vincent | PAO and PFO | S — Open-market sale [10b5-1] | 6.9K | $2.42 | $17K | SEC | |
| Vultaggio Vincent | PAO and PFO | S — Open-market sale [10b5-1] | 3.4K | $2.39 | $8K | SEC | |
| EASTLAND JULIA MARIE | CEO & President | S — Open-market sale | 889 | $2.39 | $2K | SEC | |
| Bruns Ingmar | Chief Medical Officer | S — Open-market sale | 335 | $2.39 | $802 | SEC | |
| Vultaggio Vincent | PAO and PFO | S — Open-market sale [10b5-1] | 30.0K | $2.43 | $73K | SEC | |
| EASTLAND JULIA MARIE | CEO & President | S — Open-market sale | 7.9K | $2.43 | $19K | SEC | |
| Bruns Ingmar | Chief Medical Officer | S — Open-market sale | 3.0K | $2.43 | $7K | SEC | |
| Vultaggio Vincent | PAO and PFO | S — Open-market sale [10b5-1] | 556 | $2.52 | $1K | SEC | |
| Vultaggio Vincent | PAO and PFO | S — Open-market sale [10b5-1] | 2.5K | $2.55 | $6K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Zentalis Pharmaceuticals, Inc. (ZNTL). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Myers Scott Dunseth | 1 | — |
| Campbell Shannon | 1 | — |
| Skvarka Jan | 1 | — |
| Johnson David Michael | 1 | — |
| Walker Luke Nathaniel | 1 | — |
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ZNTL insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live ZNTL dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.